Lenvatinib and pembrolizumab plus FOLFOX-hepatic arterial infusion chemotherapy in locally advanced, potentially resectable hepatocellular carcinoma

Table 4 Univariate analysis of survival factors in 38 patients with initially unresectable hepatocellular carcinoma, n (%)

Factors	Survival	Death	Hazard ratio (95%CI)	P value
Gender				0.114
Male	19 (52.8)	17 (47.2)	Reference
Female	2 (100)	0 (0)	3.297 (0.751-14.479)
Age (years)				0.725
≤ 65	18 (56.3)	14 (43.7)	Reference
> 65	3 (50.0)	3(50.0)	0.802 (0.236-2.734)
Hepatitis B				0.189
Negative	1 (25.0)	3 (75.0)	Reference
Positive	20 (58.8)	14 (41.2)	3.872 (0.514-29.169)
Liver cirrhosis				0.935
Negative	11 (55.0)	9 (45.0)	Reference
Positive	10 (55.6)	8 (44.4)	0.965 (0.41-2.274)
Antiviral therapy				0.093
Negative	14 (46.7)	16 (53.3)	Reference
Positive	7 (87.5)	1 (12.5)	2.179 (0.879-5.402)
China Liver Cancers stage				0.734
Ia	1 (100.0)	0	Reference
Ib	2 (40.0)	3 (60.0)	2.863 (0.362-22.623)	0.319
IIa	2 (66.7)	1 (33.3)	0.495 (0.113-2.172)	0.351
IIb	0	1 (100.0)	1.031 (0.236-4.498)	0.968
IIIa	16 (57.1)	12 (42.9)	0	0.983
Barcelona Clinic Liver Cancer stage				0.337
A	2 (33.3)	4 (66.7)	Reference
B	3 (75.0)	1 (25.0)	0.397 (0.09-1.746)	0.222
C	16 (57.1)	12 (42.9)	1.538 (0.442-5.353)	0.499
Hepatocellular carcinoma lesions				0.181
1	7 (43.7)	9 (56.3)	Reference
≥ 2	14 (63.6)	8 (36.4)	1.886 (0.745-4.776)
Alpha-fetoprotein (μg/L)				0.696
< 400	9 (52.9)	8 (47.1)	Reference
≥ 400	12 (57.1)	9 (42.9)	1.188 (0.5-2.823)
Conversion rate				0.011
Fail	9 (42.9)	12 (57.1)	Reference
Succes	12 (70.6)	5 (29.4)	0.272 (0.099-0.745)